Innovent Biologics, an HKEX-listed biopharmaceutical company in SIP, announced on Nov 28 that the National Medical Products Administration (NMPA) of China had approved PECONDLE? (Picankibart Injection), a recombinant anti-interleukin-23p19 subunit (IL-23p19) antibody, for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systematic therapy.
As the first of its kind independently developed by a local company in China, this new product has demonstrated superior efficacy in skin lesions clearness and supports longer maintenance dosing intervals than currently available biologics in the country, delivering a new treatment option for patients with plaque psoriasis.
The Picankibart Injection is the 17th product that Innovent has launched in market and one of the company’s key products in the field of autoimmunity. Innovent said it would continue to advance research on piconchibart in more psoriasis subtypes, psoriatic arthritis and adolescent psoriasis to meet the clinical needs of more patients.
November 29, 2025
